| Year |
Citation |
Score |
| 2024 |
Harris BHL, Di Giovannantonio M, Zhang P, Harris DA, Lord SR, Allen NE, Maughan TS, Bryant RJ, Harris AL, Bond GL, Buffa FM. New role of fat-free mass in cancer risk linked with genetic predisposition. Scientific Reports. 14: 7270. PMID 38538606 DOI: 10.1038/s41598-024-54291-7 |
0.374 |
|
| 2023 |
Clift AK, Collins GS, Lord S, Petrou S, Dodwell D, Brady M, Hippisley-Cox J. Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study. The Lancet. Digital Health. 5: e571-e581. PMID 37625895 DOI: 10.1016/S2589-7500(23)00113-9 |
0.34 |
|
| 2023 |
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, et al. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4741. PMID 37550302 DOI: 10.1038/s41467-023-40561-x |
0.333 |
|
| 2023 |
Charles Coombes R, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature Communications. 14: 4444. PMID 37488191 DOI: 10.1038/s41467-023-40061-y |
0.309 |
|
| 2023 |
Carroll TM, Chadwick JA, Owen RP, White MJ, Kaplinsky J, Peneva I, Frangou A, Xie PF, Chang J, Roth A, Amess B, James SA, Rei M, Fuchs HS, McCann KJ, ... ... Lord SR, et al. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma. Cancer Cell. 41: 1222-1241.e7. PMID 37433281 DOI: 10.1016/j.ccell.2023.06.006 |
0.328 |
|
| 2023 |
Clift AK, Dodwell D, Lord S, Petrou S, Brady M, Collins GS, Hippisley-Cox J. Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study. Bmj (Clinical Research Ed.). 381: e073800. PMID 37164379 DOI: 10.1136/bmj-2022-073800 |
0.311 |
|
| 2023 |
Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British Journal of Cancer. PMID 36823364 DOI: 10.1038/s41416-023-02204-2 |
0.481 |
|
| 2022 |
Skolariki A, D'Costa J, Little M, Lord S. Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of Targeted Anti-Tumor Therapy. 3: 172-199. PMID 36046843 DOI: 10.37349/etat.2022.00078 |
0.42 |
|
| 2022 |
Harris BHL, Macaulay VM, Harris DA, Klenerman P, Karpe F, Lord SR, Harris AL, Buffa FM. Obesity: a perfect storm for carcinogenesis. Cancer Metastasis Reviews. PMID 36038791 DOI: 10.1007/s10555-022-10046-2 |
0.579 |
|
| 2022 |
Telli ML, Tolaney SM, Shapiro GI, Middleton M, Lord SR, Arkenau HT, Tutt A, Abramson V, Dean E, Haddad TC, Wesolowski R, Ferrer-Playan J, Goddemeier T, Grombacher T, Dong J, et al. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. Npj Breast Cancer. 8: 45. PMID 35393425 DOI: 10.1038/s41523-022-00406-0 |
0.331 |
|
| 2022 |
Clift AK, Hippisley-Cox J, Dodwell D, Lord S, Brady M, Petrou S, Collins GS. Development and validation of clinical prediction models for breast cancer incidence and mortality: a protocol for a dual cohort study. Bmj Open. 12: e050828. PMID 35351695 DOI: 10.1136/bmjopen-2021-050828 |
0.305 |
|
| 2021 |
Scott NP, Teoh EJ, Flight H, Jones BE, Niederer J, Mustata L, MacLean GM, Roy PG, Remoundos DD, Snell C, Liu C, Gleeson FV, Harris AL, Lord SR, McGowan DR. Characterising F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. British Journal of Cancer. PMID 34795409 DOI: 10.1038/s41416-021-01623-3 |
0.7 |
|
| 2021 |
Howell S, Krebs M, Lord S, Kenny L, Bahl A, Clack G, Ainscow E, Arkenau H, Mansi J, Palmieri C, Richards P, Jeselsohn R, Mitri Z, Gradishar W, Sardesai S, et al. 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) Annals of Oncology. 32: S477-S478. DOI: 10.1016/j.annonc.2021.08.548 |
0.303 |
|
| 2020 |
Baird RD, Linossi C, Middleton M, Lord S, Harris A, Rodón J, Zitt C, Fiedler U, Dawson KM, Leupin N, Stumpp MT, Harstrick A, Azaro A, Fischer S, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000596. PMID 33301375 DOI: 10.1200/JCO.20.00596 |
0.409 |
|
| 2020 |
Di Giovannantonio M, Harris BH, Zhang P, Kitchen-Smith I, Xiong L, Sahgal N, Stracquadanio G, Wallace M, Blagden S, Lord S, Harris D, Harris AHL, Buffa FM, Bond GL. Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. Journal of Medical Genetics. PMID 32591342 DOI: 10.1136/Jmedgenet-2019-106799 |
0.558 |
|
| 2020 |
Aroldi F, Lord SR. Window of opportunity clinical trial designs to study cancer metabolism. British Journal of Cancer. 122: 45-51. PMID 31819180 DOI: 10.1038/s41416-019-0621-4 |
0.378 |
|
| 2019 |
Lord SR, Collins JM, Cheng WC, Haider S, Wigfield S, Gaude E, Fielding BA, Pinnick KE, Harjes U, Segaran A, Jha P, Hoefler G, Pollak MN, Thompson AM, Roy PG, et al. Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer. PMID 31819193 DOI: 10.1038/s41416-019-0665-5 |
0.763 |
|
| 2019 |
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. The Lancet. Oncology. PMID 31257177 DOI: 10.1016/S1470-2045(19)30328-6 |
0.311 |
|
| 2019 |
Morotti M, Bridges E, Valli A, Choudhry H, Sheldon H, Wigfield S, Gray N, Zois CE, Grimm F, Jones D, Teoh EJ, Cheng WC, Lord S, Anastasiou D, Haider S, et al. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 31152137 DOI: 10.1073/Pnas.1818521116 |
0.671 |
|
| 2018 |
Lord SR, Cheng WC, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson F, Bradley K, Wigfield S, Zois C, McGowan DR, Ah-See ML, Thompson AM, et al. Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism. PMID 30244975 DOI: 10.1016/J.Cmet.2018.08.021 |
0.739 |
|
| 2018 |
Saura C, Thistlethwaite F, Banerji U, Lord S, Moreno V, MacPherson I, Boni V, Rolfo CD, de Vries EG, Van Herpen CM, Rottey S, Geenen JJ, Eskens F, Gil Martin M, Mommers E, et al. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer. Journal of Clinical Oncology. 36: 1014-1014. DOI: 10.1200/JCO.2018.36.15_SUPPL.1014 |
0.364 |
|
| 2017 |
Morotti M, Dass PH, Harris AL, Lord S. Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. European Journal of Drug Metabolism and Pharmacokinetics. PMID 29019020 DOI: 10.1007/s13318-017-0442-x |
0.748 |
|
| 2017 |
Telli M, Lord S, Dean E, Abramson V, Arkenau H, Becerra C, Tolaney S, Tang R, Penney M, Pollard J, Conboy G, Fields S, Shapiro G. Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792) Annals of Oncology. 28: v76. DOI: 10.1093/ANNONC/MDX365.005 |
0.331 |
|
| 2016 |
Mehta S, Hughes NP, Li S, Jubb A, Adams R, Lord S, Koumakis L, van Stiphout R, Padhani A, Makris A, Buffa FM, Harris AL. Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. Ebiomedicine. PMID 27474395 DOI: 10.1016/j.ebiom.2016.07.017 |
0.753 |
|
| 2016 |
Lord S, Funes JM, Harris AL, Quintela-Fandino M. Antiangiogenic resistance and cancer metabolism: opportunities for synthetic lethality. Current Drug Targets. PMID 26953245 DOI: 10.2174/1389450117666160307143718 |
0.54 |
|
| 2016 |
Lord S, Liu D, Cheng W, Haider S, Gaude E, Teoh E, Patel N, Metcalf T, McGowan D, Roxanis I, Qifeng Z, Roy P, Gleeson F, Thompson A, Pollak M, et al. Metformin increases 18F-FDG flux and inhibits fatty acid oxidation at clinical doses in breast cancer: Results of a phase 0 clinical trial European Journal of Surgical Oncology (Ejso). 42: S230. DOI: 10.1016/J.Ejso.2016.07.060 |
0.636 |
|
| 2015 |
Lord SR, Patel N, Liu D, Fenwick J, Gleeson F, Buffa F, Harris AL. Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism. Journal of the National Cancer Institute. Monographs. 2015: 81-6. PMID 26063894 DOI: 10.1093/jncimonographs/lgv011 |
0.535 |
|
| 2015 |
Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, Domarkas J, Lord S, Baldry C, Gilbert FJ. Imaging tumour hypoxia with positron emission tomography. British Journal of Cancer. 112: 238-50. PMID 25514380 DOI: 10.1038/bjc.2014.610 |
0.4 |
|
| 2014 |
Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li JL, Zhang Q, Wakelam MJ, Karpe F, Schulze A, Harris AL. Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Reports. 9: 349-65. PMID 25263561 DOI: 10.1016/j.celrep.2014.08.056 |
0.696 |
|
| 2011 |
Favaro E, Lord S, Harris AL, Buffa FM. Gene expression and hypoxia in breast cancer. Genome Medicine. 3: 55. PMID 21875443 DOI: 10.1186/gm271 |
0.78 |
|
| 2011 |
Crighton J, Hall P, Lord S, Perrin T, Dodwell D. Surgical resection of isolated breast cancer recurrence within the sternum Bone. 48. DOI: 10.1016/J.Bone.2010.10.058 |
0.301 |
|
| 2010 |
Lord S, Harris AL. Angiogenesis - still a worthwhile target for breast cancer therapy? Breast Cancer Research : Bcr. 12: S19. PMID 21172081 DOI: 10.1186/bcr2748 |
0.536 |
|
| 2009 |
Lord SR, Vasudev N, Knight S, Speirs V, Hall G. Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e16551. PMID 27960814 DOI: 10.1200/jco.2009.27.15_suppl.e16551 |
0.318 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2020 |
Chandarlapaty S, Bardia A, Lord S, Linden H, Pelekanou V, Ternes N, Ming J, Boutet V, Boitier E, Gosselin A, Lee JS, Dos-Santos Bele W, Protopopov A, Celanovic M, Bauchet A, et al. 277MO SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2- metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study Annals of Oncology. 31: S351. DOI: 10.1016/j.annonc.2020.08.379 |
0.288 |
|
| 2017 |
Hall PS, Lord SR, Collinson M, Marshall H, Jones M, Lowe C, Howard H, Swinson D, Velikova G, Anthoney A, Roy R, Dent J, Cheeseman S, Last K, Seymour MT. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). British Journal of Cancer. PMID 28095397 DOI: 10.1038/Bjc.2016.442 |
0.286 |
|
| 2015 |
Tjokrowidjaja A, Lee CK, Houssami N, Lord S. Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis. Internal Medicine Journal. 44: 764-70. PMID 24863750 DOI: 10.1111/imj.12481 |
0.286 |
|
| 2010 |
Lord SR, Hall PS, McShane P, Brown J, Seymour MT. Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy. Clinical Oncology (Royal College of Radiologists (Great Britain)). 22: 107-13. PMID 20053542 DOI: 10.1016/j.clon.2009.12.001 |
0.283 |
|
| 2022 |
Greene J, Segaran A, Lord S. Targeting OXPHOS and the electronic transport chain in cancer; Molecular and therapeutic implications. Seminars in Cancer Biology. PMID 35122973 DOI: 10.1016/j.semcancer.2022.02.002 |
0.282 |
|
| 2021 |
Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, Tillett T, Nicoll J, Cummins S, Mano J, Grumett S, ... ... Lord S, et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 33983395 DOI: 10.1001/jamaoncol.2021.0848 |
0.28 |
|
| 2010 |
Hall PS, Lord SR, El-Laboudi A, Seymour MT. Non-cancer medications for patients with incurable cancer: time to stop and think? The British Journal of General Practice : the Journal of the Royal College of General Practitioners. 60: 243-4. PMID 20353669 DOI: 10.3399/bjgp10X483887 |
0.278 |
|
| 2024 |
Spiliopoulou P, Kazmi F, Aroldi F, Holmes T, Thompson D, Griffiths L, Qi C, Parkes M, Lord S, Veal GJ, Harrison DJ, Coyle VM, Graham J, Jeffry Evans TR, Blagden SP. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental & Clinical Cancer Research : Cr. 43: 100. PMID 38566164 DOI: 10.1186/s13046-024-03010-1 |
0.276 |
|
| 2012 |
Hall PS, Lord S, Collinson M, Marshall H, Jones M, Olivier C, Howard H, Seligman J, Swinson D, Roy R, Dent J, Cheeseman S, Last KW, Seymour MT. Three, two, or one drug chemotherapy for frail or elderly patients with advanced gastroesophageal cancer (321GO): A feasibility study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 97. PMID 27983395 DOI: 10.1200/jco.2012.30.4_suppl.97 |
0.274 |
|
| 2015 |
Coupe N, Gupta A, Lord SR. Early phase cancer clinical trials: design, ethics and future directions. British Journal of Hospital Medicine (London, England : 2005). 76: 409-13. PMID 26140560 DOI: 10.12968/hmed.2015.76.7.409 |
0.272 |
|
| 2023 |
Pagnamenta AT, Camps C, Giacopuzzi E, Taylor JM, Hashim M, Calpena E, Kaisaki PJ, Hashimoto A, Yu J, Sanders E, Schwessinger R, Hughes JR, Lunter G, Dreau H, Ferla M, ... ... Lord SR, et al. Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases. Genome Medicine. 15: 94. PMID 37946251 DOI: 10.1186/s13073-023-01240-0 |
0.272 |
|
| 2022 |
Henriksen PA, Hall P, Oikonomidou O, MacPherson IR, Maclean M, Lewis S, McVicars H, Broom A, Scott F, McKay P, Borley A, Rowntree C, Lord S, Collins G, Radford J, et al. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. Circulation. Heart Failure. 101161CIRCHEARTFAILU. PMID 35766037 DOI: 10.1161/CIRCHEARTFAILURE.121.009445 |
0.263 |
|
| 2021 |
Kazmi F, Shrestha N, Booth S, Dodwell D, Aroldi F, Foord T, Nicholson BD, Heesen P, Lord S, Yeoh K, Blagden S. Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer Cochrane Database of Systematic Reviews. 2021. DOI: 10.1002/14651858.cd014872 |
0.26 |
|
| 2021 |
Campone M, Bardia A, Kabos P, Chandarlapaty S, Neven P, Boni V, Lord S, Cartot-Cotton S, Celanovic M, Gosselin A, Pelekanou V, Linden H. 333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer Annals of Oncology. 32: S511-S512. DOI: 10.1016/j.annonc.2021.08.616 |
0.243 |
|
| 2019 |
Swinson D, Hall P, Lord S, Marshall H, Ruddock S, Allmark C, Cairns D, Waters J, Wadsley J, Falk S, Roy R, Joseph M, Nicoll J, Kamposioras K, Tillett T, et al. OPTIMIZING CHEMOTHERAPY FOR FRAIL AND/OR ELDERLY PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER (AGOAC): THE GO2 PHASE III TRIAL Journal of Geriatric Oncology. 10: S8. DOI: 10.1016/s1879-4068(19)31133-6 |
0.243 |
|
| 2019 |
Thomas A, Virdee PS, Eatock M, Lord SR, Falk S, Anthoney DA, Turkington RC, Goff M, Elhussein L, Collins L, Love S, Moschandreas J, Middleton MR. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. European Journal of Cancer (Oxford, England : 1990). 124: 131-141. PMID 31765988 DOI: 10.1016/j.ejca.2019.10.010 |
0.232 |
|
| 2024 |
Dixon-Zegeye M, Shaw R, Collins L, Perez-Smith K, Ooms A, Qiao M, Pantziarka P, Izatt L, Tischkowitz M, Harrison RE, George A, Woodward ER, Lord S, Hawkes L, Evans DG, et al. Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol. Trials. 25: 103. PMID 38308321 DOI: 10.1186/s13063-024-07929-w |
0.226 |
|
| 2021 |
Clift AK, Dodwell D, Lord S, Petrou S, Brady SM, Collins GS, Hippisley-Cox J. The current status of risk-stratified breast screening. British Journal of Cancer. PMID 34703006 DOI: 10.1038/s41416-021-01550-3 |
0.218 |
|
| 2023 |
Macaulay VM, Lord S, Hussain S, Maroto JP, Jones RH, Climent MÁ, Cook N, Lin CC, Wang SS, Bianchini D, Bailey M, Schlieker L, Bogenrieder T, de Bono J. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. British Journal of Cancer. PMID 37537253 DOI: 10.1038/s41416-023-02380-1 |
0.204 |
|
| 2019 |
Hall P, Swinson D, Lord S, Handforth C, Cairns D, Marshall H, Petty R, Bennett M, Velikova G, Seymour M. Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial Annals of Oncology. 30: v879-v880. DOI: 10.1093/annonc/mdz394.037 |
0.189 |
|
| 2012 |
Seligmann JF, Hall P, Hamilton P, Lord SR, Baxter P, Marples M, Stark DP. D-dimers as a tumor marker in GIST: Can it reduce the frequency of CT scanning in patients receiving palliative imatinib? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 119. PMID 27983083 DOI: 10.1200/Jco.2012.30.4_Suppl.119 |
0.186 |
|
| 2010 |
Lord S, Hall PS, Seymour MT. Concomitant medications in cancer patients: Should we be more active in their management? Annals of Oncology. 21: 430. DOI: 10.1093/Annonc/Mdp539 |
0.183 |
|
| 2022 |
Cheng VWT, de Pennington N, Zakaria R, Larkin JR, Serres S, Sarkar M, Kirkman MA, Bristow C, Croal P, Plaha P, Campo L, Chappell MA, Lord S, Jenkinson MD, Middleton MR, et al. VCAM-1-targeted magnetic resonance imaging improves detection of the tumor-brain interface. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35312755 DOI: 10.1158/1078-0432.CCR-21-4011 |
0.159 |
|
| 1988 |
Segal I, Walker AR, Lord S, Cummings JH. Breath methane and large bowel cancer risk in contrasting African populations. Gut. 29: 608-13. PMID 3396948 DOI: 10.1136/gut.29.5.608 |
0.153 |
|
| 2020 |
Sivakumar S, Rana A, Seth C, de Santiago I, Soonawalla Z, Morgan R, Rendek A, Silva M, Reddy S, Jones S, Nicod J, Turnquist C, Tandon R, O’Neill E, Lord S, et al. Genomic profiling in pancreatic cancer reveals spatial genetic heterogeneity but spatial transcriptomic homogeneity Pancreatology. 20: e9. DOI: 10.1016/j.pan.2018.10.037 |
0.149 |
|
| 2015 |
Afshar M, Hamilton P, Seligmann J, Lord S, Baxter P, Marples M, Stark D, Hall PS. Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)? Cancer Investigation. PMID 26135352 DOI: 10.3109/07357907.2015.1047504 |
0.145 |
|
| 2019 |
Swinson D, Hingorani M, Stokes Z, Dent J, Guptal K, Chatterjee A, Kamposioras K, Grumett SA, Khan M, Marshall H, Ruddock S, Allmark C, Katona E, Howard HC, Velikova G, ... Lord S, et al. Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial. Journal of Clinical Oncology. 37: 4051-4051. DOI: 10.1200/JCO.2019.37.15_SUPPL.4051 |
0.13 |
|
| 2023 |
Virani F, Carey M, Kazmi F, Blagden S, Lord S, Miller M. Early phase antitumour clinical trials and palliative medicine. Bmj Supportive & Palliative Care. PMID 37507202 DOI: 10.1136/spcare-2023-004496 |
0.124 |
|
| 2021 |
Schmid P, Im S, Armstrong A, Park YH, Chung W, Nowecki Z, Lord S, Wysocki PJ, Lu Y, Dry H, Karwe V, Stewart R, Herbolsheimer P, Nunes AT, Jung KH. BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). Journal of Clinical Oncology. 39: 1023-1023. DOI: 10.1200/JCO.2021.39.15_SUPPL.1023 |
0.119 |
|
| 2023 |
Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, Lewis S, Rodriguez A, Fletcher A, Everett RJ, Stavert H, Broom A, Eddie L, Primrose L, McVicars H, ... ... Lord S, et al. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. Circulation. PMID 37746692 DOI: 10.1161/CIRCULATIONAHA.123.064274 |
0.115 |
|
| 2021 |
Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. British Journal of Cancer. PMID 34040174 DOI: 10.1038/s41416-021-01406-w |
0.109 |
|
| 2021 |
Spiliopoulou P, Kazmi F, Aroldi F, Holmes J, Graham J, Holmes T, Lord S, Veal G, Qi C, Coyle V, Evans T, Blagden S. 549P Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301) Annals of Oncology. 32: S610. DOI: 10.1016/j.annonc.2021.08.1071 |
0.109 |
|
| 2021 |
Krebs M, Lord S, Kenny L, Baird R, MacPherson I, Bahl A, Clack G, Ainscow E, Barrett A, Dickinson P, Fuchter M, Lehnert M, Ali S, Mcintosh S, Coombes R. 230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies Annals of Oncology. 32: S458. DOI: 10.1016/j.annonc.2021.08.513 |
0.104 |
|
| 2011 |
Hamilton P, Hall P, Seligmann J, Lord S, Marples M, Stark D. 9406 ORAL Can Serum D-dimer Monitoring Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gasto-intestinal Stromal Tumour (GIST)? European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)72550-3 |
0.081 |
|
| 2009 |
Lord SR, Hall PS, Seymour MT. Are we representing the true population in oncology trials? Annals of Oncology : Official Journal of the European Society For Medical Oncology. 20: 2022; author reply 2. PMID 19759187 DOI: 10.1093/annonc/mdp461 |
0.075 |
|
| Hide low-probability matches. |